| Project/Area Number |
24592026
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
AJIKI TETSUO 神戸大学, 医学部附属病院, 教授 (80379403)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HORI Yuuichi 神戸大学, 保健学研究科, 教授 (80248004)
GU Eisei 神戸大学, 医学研究科, 教授 (40195615)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥390,000 (Direct Cost: ¥300,000、Indirect Cost: ¥90,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2012: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Keywords | 胆道癌 / 癌幹細胞 / CD133 / 胆道がん |
|---|
| Outline of Final Research Achievements |
Systemic chemotherapy is usually indicated for patients with advanced biliary tract (BT) cancer, but response rates of chemotherapeutic agents for this tumor is quite low. We hypothesized that the low response rate is related to the existence of cancer stem cells. We examined CD 133 expression, a cancer stem cell marker, in biliary tract cancers. While no CD133 expression was observed in IPNB (low malignant tumor of BT) tumor, about 20% of cancer cells in conventional bile duct cancer cells expressed CD133. Moreover, about 80% of cancer cells of resected BT cancer cases after chemotherapy showed CD 133 expression. These results indicated that CD133 expression might be highly related to malignant potential of BT cancers or the resistance to the chemotherapeutic agents. In addition, we successes establishments both of CD133 positive and CD133 negative cancer cell lines from resected BT cancer cases.
|
